AU2010305805B2 - Macrocyclic integrase inhibitors - Google Patents

Macrocyclic integrase inhibitors Download PDF

Info

Publication number
AU2010305805B2
AU2010305805B2 AU2010305805A AU2010305805A AU2010305805B2 AU 2010305805 B2 AU2010305805 B2 AU 2010305805B2 AU 2010305805 A AU2010305805 A AU 2010305805A AU 2010305805 A AU2010305805 A AU 2010305805A AU 2010305805 B2 AU2010305805 B2 AU 2010305805B2
Authority
AU
Australia
Prior art keywords
mmol
methyl
mixture
naphthyridine
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2010305805A
Other languages
English (en)
Other versions
AU2010305805A1 (en
Inventor
Jean-Francois Bonfanti
Jerome Michel Claude Fortin
Johannes Wilhelmus J. Thuring
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elanco Animal Health Ireland Ltd
Original Assignee
Elanco Animal Health Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elanco Animal Health Ireland Ltd filed Critical Elanco Animal Health Ireland Ltd
Publication of AU2010305805A1 publication Critical patent/AU2010305805A1/en
Application granted granted Critical
Publication of AU2010305805B2 publication Critical patent/AU2010305805B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/18Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D515/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D515/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D515/18Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2010305805A 2009-10-13 2010-10-13 Macrocyclic integrase inhibitors Active AU2010305805B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09172853.5 2009-10-13
EP09172853 2009-10-13
PCT/EP2010/065300 WO2011045330A1 (en) 2009-10-13 2010-10-13 Macrocyclic integrase inhibitors

Publications (2)

Publication Number Publication Date
AU2010305805A1 AU2010305805A1 (en) 2012-04-19
AU2010305805B2 true AU2010305805B2 (en) 2014-04-03

Family

ID=41720665

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010305805A Active AU2010305805B2 (en) 2009-10-13 2010-10-13 Macrocyclic integrase inhibitors

Country Status (15)

Country Link
US (1) US8497270B2 (enExample)
EP (1) EP2488521B1 (enExample)
JP (1) JP5624148B2 (enExample)
KR (1) KR20120087916A (enExample)
CN (1) CN102574854B (enExample)
AU (1) AU2010305805B2 (enExample)
BR (1) BR112012008586A2 (enExample)
CA (1) CA2777664C (enExample)
EA (1) EA019558B1 (enExample)
ES (1) ES2446720T3 (enExample)
IL (1) IL218845A0 (enExample)
MX (1) MX2012004426A (enExample)
NZ (1) NZ598766A (enExample)
WO (1) WO2011045330A1 (enExample)
ZA (1) ZA201202516B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2487176A1 (en) * 2011-02-14 2012-08-15 Elanco Animal Health Ireland Limited Macrocyclic integrase inhibitors for use in the treatment of feline immunodeficiency virus
WO2014008636A1 (en) * 2012-07-11 2014-01-16 Merck Sharp & Dohme Corp. Macrocyclic compounds as hiv integrase inhibitors
EP2931730B1 (en) 2012-12-17 2019-08-07 Merck Sharp & Dohme Corp. 4-pyridinonetriazine derivatives as hiv integrase inhibitors
EP2986291B1 (en) 2013-04-16 2020-05-27 Merck Sharp & Dohme Corp. 4-pyridone derivative compounds and uses thereof as hiv integrase inhibitors
AU2014267951A1 (en) 2013-05-17 2015-11-19 Merck Sharp & Dohme Corp. Fused Tricyclic Heterocyclic compounds as HIV integrase inhibitors
WO2014200880A1 (en) 2013-06-13 2014-12-18 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
JP6081662B2 (ja) 2013-09-27 2017-02-15 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. Hivインテグラーゼ阻害薬として有用な置換されたキノリジン誘導体
PL3097107T3 (pl) 2014-01-24 2020-01-31 Turning Point Therapeutics, Inc. Diarylowe związki makrocykliczne jako modulatory kinaz białkowych
WO2016187788A1 (en) 2015-05-25 2016-12-01 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds useful for treating hiv infection
AU2016287568B2 (en) * 2015-07-02 2020-08-20 Turning Point Therapeutics, Inc. Chiral diaryl macrocycles as modulators of protein kinases
HRP20240780T1 (hr) 2015-07-06 2024-09-13 Turning Point Therapeutics, Inc. Polimorf diaril makrocikla
KR102772574B1 (ko) 2015-07-21 2025-02-24 터닝 포인트 테라퓨틱스, 인크. 키랄 디아릴 매크로사이클 및 이것의 용도
EP3377066B1 (en) 2015-11-17 2021-04-07 Merck Sharp & Dohme Corp. Amido-substituted pyridotriazine derivatives useful as hiv integrase inhibitors
WO2017106071A1 (en) 2015-12-15 2017-06-22 Merck Sharp & Dohme Corp. Spirocyclic quinolizine derivatives useful as hiv integrase inhibitors
WO2017113288A1 (en) 2015-12-31 2017-07-06 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
JOP20190130A1 (ar) 2016-12-02 2019-06-02 Merck Sharp & Dohme مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv)
RU2749043C2 (ru) 2016-12-02 2021-06-03 Мерк Шарп И Доум Корп. Трициклические гетероциклические соединения, полезные в качестве ингибиторов интегразы вич
TWI808958B (zh) 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
EP3573984A4 (en) 2017-01-26 2020-07-29 Merck Sharp & Dohme Corp. USEFUL SUBSTITUTE QUINOLIZINE DERIVATIVES AS HIV INTEGRASE INHIBITORS
JP7224334B2 (ja) 2017-07-28 2023-02-17 ターニング・ポイント・セラピューティクス・インコーポレイテッド 大環式化合物およびその使用
SI3728271T1 (sl) 2017-12-19 2023-01-31 Turning Point Therapeutics, Inc. Makrociklične spojine za zdravljenje bolezni
HUE059677T2 (hu) 2019-03-22 2022-12-28 Gilead Sciences Inc Áthidalt triciklusos karbamoilpiridon-vegyületek és ezek gyógyszerészeti alkalmazása
CR20220418A (es) 2020-02-24 2022-10-10 Gilead Sciences Inc Compuestos tetracíclicos para el tratamiento de infecciones por vih
JP7691494B2 (ja) 2020-09-30 2025-06-11 ギリアード サイエンシーズ, インコーポレイテッド 架橋三環式カルバモイルピリドン化合物及びその使用
CN112358477A (zh) * 2020-11-10 2021-02-12 牡丹江医学院 一种用于治疗胆囊炎的药物及其制备方法
LT4196479T (lt) 2021-01-19 2023-12-11 Gilead Sciences, Inc. Pakeistieji piridotriazino junginiai ir jų panaudojimo būdai
TWI843506B (zh) 2022-04-06 2024-05-21 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
CN115974886A (zh) * 2022-11-22 2023-04-18 国科大杭州高等研究院 一种含有二氢苯并呋喃骨架的大环内酰胺化合物及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002030931A2 (en) * 2000-10-12 2002-04-18 Merck & Co., Inc. Aza- and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CS210880B1 (cs) 1979-10-19 1982-01-29 Jiri Krepelka Substituované imidy kyselin 4-arylnaftalen-2,3-dikarboxylových
CS225002B1 (cs) 1980-12-12 1984-02-13 Krepelka Jiri Deriváty 9-fenyl-1H-benzo/f/isoindol-1,3-dionu a způsob jejich výroby
JPH04217684A (ja) 1990-05-30 1992-08-07 Shionogi & Co Ltd アルド−ス還元酵素阻害物質
WO1996008478A1 (en) * 1994-09-13 1996-03-21 Kyowa Hakko Kogyo Co., Ltd. Anti-hiv drug
ATE345129T1 (de) 2000-10-12 2006-12-15 Merck & Co Inc Aza- und polyaza-naphthalenylcarbonsäureamide als hiv-integrase-hemmer
ES2287170T3 (es) 2000-10-12 2007-12-16 MERCK & CO., INC. Aza- y poliaza-naftalenil-carboxamidas utilies como inhibidores de la vih integrasa.
US20050010048A1 (en) 2000-10-12 2005-01-13 Linghang Zhuang Aza-and polyaza-naphthalenly ketones useful as hiv integrase inhibitors
WO2004035577A2 (en) 2002-10-16 2004-04-29 Gilead Sciences, Inc. Pre-organized tricyclic integrase inhibitor compounds
DE60329318D1 (de) 2002-11-20 2009-10-29 Japan Tobacco Inc 4-oxochinolinverbindungen und deren verwendung als hiv-integrase-inhibitoren
AU2003292436B2 (en) 2002-12-27 2009-07-30 Msd Italia S.R.L. Tetrahydro-4H-pyrido[1,2-A]pyrimidines and related compounds useful as HIV integrase inhibitors
US6890942B2 (en) 2003-05-16 2005-05-10 Bristol-Myers Squibb Company Acyl sulfonamides as inhibitors of HIV integrase
EP1664046B1 (en) 2003-09-19 2009-06-17 Gilead Sciences, Inc. Aza-quinolinol phosphonate integrase inhibitor compounds
WO2005087766A1 (en) 2004-03-09 2005-09-22 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Hiv integrase inhibitors
US7176196B2 (en) 2004-05-28 2007-02-13 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors
KR101580310B1 (ko) 2005-04-28 2016-01-04 비이브 헬쓰케어 컴퍼니 Hiv 통합효소 억제 활성을 가지는 다환식 카르바모일피리돈 유도체
EP1910363A4 (en) * 2005-08-04 2010-05-26 Glaxosmithkline Llc INHIBITORS OF HIV INTEGRASE
CA2626956A1 (en) * 2005-10-27 2007-05-03 Shionogi & Co., Ltd. Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity
US8039458B2 (en) * 2005-11-17 2011-10-18 Bristol-Myers Squibb Company HIV integrase inhibitors
TW200811153A (en) 2006-06-23 2008-03-01 Japan Tobacco Inc 6-(heterocyclyl-substituted benzyl)-4-oxoquinoline compound and use thereof as HIV integrase inhibitor
JP5480824B2 (ja) * 2008-03-10 2014-04-23 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Plkキナーゼ阻害剤としての4−アリール−2−アニリノ−ピリミジン

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002030931A2 (en) * 2000-10-12 2002-04-18 Merck & Co., Inc. Aza- and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors

Also Published As

Publication number Publication date
EP2488521B1 (en) 2013-12-18
EA019558B1 (ru) 2014-04-30
CA2777664A1 (en) 2011-04-21
KR20120087916A (ko) 2012-08-07
JP2013507423A (ja) 2013-03-04
CA2777664C (en) 2014-06-10
ZA201202516B (en) 2013-09-25
NZ598766A (en) 2013-09-27
AU2010305805A1 (en) 2012-04-19
CN102574854B (zh) 2014-04-16
IL218845A0 (en) 2012-06-28
MX2012004426A (es) 2012-07-30
BR112012008586A2 (pt) 2016-11-29
US20120172367A1 (en) 2012-07-05
CN102574854A (zh) 2012-07-11
US8497270B2 (en) 2013-07-30
WO2011045330A1 (en) 2011-04-21
EA201270540A1 (ru) 2012-09-28
JP5624148B2 (ja) 2014-11-12
ES2446720T3 (es) 2014-03-10
EP2488521A1 (en) 2012-08-22

Similar Documents

Publication Publication Date Title
AU2010305805B2 (en) Macrocyclic integrase inhibitors
WO2021088458A1 (en) Kras mutant protein inhibitor
WO2021057832A1 (en) Kras mutant protein inhibitor
AU2023248067A1 (en) Cereblon ligands and bifunctional compounds comprising the same
EP2906563B1 (en) Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
ES2470570T3 (es) Pirimidinas sustituidas en posición 6 inhibidoras del HIV
JP5739517B2 (ja) 大環状インテグラーゼ阻害剤
KR101953869B1 (ko) 베툴린의 유도체
US5624924A (en) Quinobenzothiazine antineoplastic agents
KR20180029061A (ko) 단백질 분해의 알라닌계 조절인자 및 관련된 이용 방법
HK1221952A1 (zh) 作为bet蛋白和极体样激酶的双重抑制剂的取代的二氢吡啶并[3,4-b]吡嗪酮
CA3121140A1 (en) Compounds useful in hiv therapy
BRPI0717089A2 (pt) Derivados de quinolinona
EP2487176A1 (en) Macrocyclic integrase inhibitors for use in the treatment of feline immunodeficiency virus
EP0608215A1 (en) Quinobenzoxazine, quinobenzothiazine, and pyrido-acridine antineoplastic agents
HK1172012B (en) Macrocyclic integrase inhibitors
HK1172012A (en) Macrocyclic integrase inhibitors
AU2012218004A1 (en) Macrocyclic integrase inhibitors for use in the treatment of feline immunodeficiency virus

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)